SCYNEXIS
SCYNEXIS, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for ... patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is based in Durham, North Carolina.
SCYNEXIS
Industry:
Biotechnology Health Care Manufacturing Pharmaceutical
Founded:
1999-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.scynexis.com
Total Employee:
51+
Status:
Active
Contact:
9195448697
Total Funding:
251.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - SCYNEXIS
Hercules Capital
Hercules Capital investment in Post-IPO Debt - SCYNEXIS
Armentum Partners
Armentum Partners investment in Debt Financing - SCYNEXIS
Key Employee Changes
| Date | New article |
|---|---|
| 2020-06-02 | SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales |
Official Site Inspections
http://www.scynexis.com Semrush global rank: 1.31 M Semrush visits lastest month: 22.46 K
- Host name: 925465.cloudwaysapps.com
- IP address: 157.245.246.148
- Location: North Bergen United States
- Latitude: 40.793
- Longitude: -74.0247
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07047
More informations about "SCYNEXIS"
About - Scynexis
Our mission. All around the world, millions of people suffer from pernicious fungal diseases. At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing …See details»
SCYNEXIS, Inc. (SCYX)
Company. SCYNEXIS, Inc. 1 Evertrust Plaza 13th Floor Jersey City, NJ 07302 T: (201) 884-5485See details»
Company Information :: SCYNEXIS, Inc. (SCYX)
SCYNEXIS, Inc. 1 Evertrust Plaza 13th Floor Jersey City, NJ 07302 T: (201) 884-5485 [email protected]. Investor Relations LifeSci Advisors Irina Koffler T: 646-970-4681 [email protected]. Email Alerts; Company Profile; …See details»
SCYNEXIS - Crunchbase Company Profile & Funding
Additionally, SCYNEXIS's earnings and revenue have grown, as evidenced by a report stating that earnings have beaten expectations and revenue is projected to grow by 8.4%. …See details»
Leadership - Scynexis
Daniella Gigante joined SCYNEXIS to lead the Human Resources and IT functions in October 2020. She has over 22 years of Human Resources experience in various industries including Consulting, Banking, …See details»
SCYNEXIS, Inc. - AnnualReports.com
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are …See details»
SCYNEXIS, Inc. (SCYX) Company Profile & Facts - Yahoo Finance
See the company profile for SCYNEXIS, Inc. (SCYX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
SCYNEXIS, Inc. (SCYX) Company Profile & Facts - Yahoo Finance
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is …See details»
SCYNEXIS - Org Chart, Teams, Culture & Jobs - The Org
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are …See details»
SCYNEXIS - Funding, Financials, Valuation & Investors - Crunchbase
SCYNEXIS is registered under the ticker NASDAQ:SCYX . Their stock opened with $10.00 in its May 9, 2014 IPO. Stock Symbol NASDAQ:SCYX ; Valuation at IPO $84M; Money Raised at …See details»
Company SCYNEXIS, Inc. - MarketScreener.com
Nov 30, 2008 SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal …See details»
Scynexis Company Profile - Office Locations, Competitors ... - Craft
Sep 6, 2024 Scynexis has 5 employees at their 1 location and $140.14 m in annual revenue in FY 2023. See insights on Scynexis including office locations, competitors, revenue, financials, …See details»
SCYNEXIS - Overview, News & Similar companies | ZoomInfo.com
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: …See details»
Contact Us - Scynexis
SCYNEXIS, Inc. 1 Evertrust Plaza 13th Floor Jersey City, NJ 07302 (201) 884-5485. Work with us. A leading stand-alone anti-infective company, we are working to build a broad, long-lasting …See details»
SCYNEXIS, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. ... The statistics for …See details»
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second ...
5 days ago JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome …See details»
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second ...
5 days ago JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome …See details»
SCYNEXIS Begins Phase 1 Trial Of SCY-247 For Severe Invasive
4 days ago It also demonstrates activity against many fungi on the World Health Organization's (WHO) fungal priority pathogen list. SCYNEXIS anticipates that the U.S. Food and Drug …See details»
SCYNEXIS Provides Corporate, Commercial and R&D Strategy …
Oct 20, 2022 SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher …See details»
Our Science - Scynexis
Next-generation triterpenoid antifungals (the fungerps) When working in the field of life-threatening infectious diseases, you are racing against rapidly evolving pathogens.See details»